Teva projects strong revenue growth at J.P. Morgan Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 Jan 26
Source: SeekingAlpha
Teva Pharmaceutical Industries Ltd saw its stock rise by 4.15% as it reached a 52-week high amid broader market declines.
At the J.P. Morgan Healthcare Conference, Teva showcased its 'Pivot to Growth' strategy, projecting revenues of $16.8 billion to $17.0 billion for 2025, which has boosted investor confidence. The company also highlighted key innovative brands like AUSTEDO® and AJOVY® that are expected to significantly contribute to future financial performance, indicating a strong growth trajectory.
This positive outlook reflects Teva's commitment to innovation and financial stability, positioning the company favorably in the competitive biopharmaceutical market.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.210
Low
29.00
Averages
35.71
High
40.00
Current: 33.210
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
